GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » Marketable Securities

Phio Pharmaceuticals (Phio Pharmaceuticals) Marketable Securities : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Phio Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2024 was $0.00 Mil.


Phio Pharmaceuticals Marketable Securities Historical Data

The historical data trend for Phio Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals Marketable Securities Chart

Phio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Phio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Phio Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Phio Pharmaceuticals  (NAS:PHIO) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".


Phio Pharmaceuticals Marketable Securities Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Phio Pharmaceuticals (Phio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.
Executives
Robert J Bitterman director C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford director UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh director, officer: President and CEO 1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev officer: Chief Business Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman director 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc. 10 percent owner 4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc 10 percent owner 1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco officer: Chief Development Officer C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis officer: Secretary and Controller 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581

Phio Pharmaceuticals (Phio Pharmaceuticals) Headlines

From GuruFocus

Phio Pharmaceuticals Announces Reverse Stock Split

By PRNewswire PRNewswire 01-25-2023